ArticleForensic science international. Mind and law2020
United States drug courts and opioid agonist therapy: Missing the target of overdose reduction.
Article in Forensic science international. Mind and law, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 20 citations in OpenAlex.
- Modeling the effect of drug courts in North Carolina counties.Research square · 2026Article
- Assessing the effectiveness of problem-solving courts on the reduction of overdose deaths in the United States: A difference-in-difference study.Drug and alcohol dependence reports · 2022Article
- Substance misuse and community supervision: A systematic review of the literature.Forensic science international. Mind and law · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
•Agonist therapy for opioid use disorder (OUD) is often inaccessible in the US at a time of high overdose mortality.•OUD therapy could be offered by drug treatment courts as an alternative to criminal prosecution for some drug offenses.•Many drug courts, however, reject gold-standard agonist therapies, seeing them as "another form of addiction".•Drug courts often prefer to offer extended-release naltrexone, but it is costly and requires pre-treatment abstinence.•Drug courts have had limited success in improving access to OUD treatment at a time of high overdose mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.